

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Tc-99m-Labeling of Modified RNA

Christoph S. Hilger^a; Michael C. Willis^b; Mark Wolters^a; Wolfgang A. Pieken^b

^a Schering AG, Research Laboratories, Berlin, FRG ^b NeXstar Pharmaceuticals, Boulder, Colorado, USA

To cite this Article Hilger, Christoph S. , Willis, Michael C. , Wolters, Mark and Pieken, Wolfgang A.(1999) 'Tc-99m-Labeling of Modified RNA', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 6, 1479 — 1481

To link to this Article: DOI: 10.1080/07328319908044759

URL: <http://dx.doi.org/10.1080/07328319908044759>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Tc-99m-LABELING OF MODIFIED RNA

Christoph S. Hilger^{1*}, Michael C. Willis², Mark Wolters¹, Wolfgang A. Pieken²

¹Schering AG, Research Laboratories, Muellerstr. 178, 13342 Berlin, FRG;

²NeXstar Pharmaceuticals, 2860 Wilderness Place, Boulder, Colorado 80301, USA.

ABSTRACT: The synthesis of Tc-99m-labeled, modified RNA is reported. This new class of radiopharmaceuticals is of potential interest as target specific imaging agents. The preparation of N₃S-RNA was achieved by coupling protected MAG₂-units to amino modified ON's. The N₃S-RNA was Tc-99m-labeled with 90-95% radiochemical yield and specific activities of 37MBq/nmol leading to 1:1-Tc-99m-N₃S-aptamers.

Oligonucleotides (ON's) with rigid secondary structures and sub-nM affinities for extracellular targets can be identified by the SELEX-process¹. Radioactive labeled aptamers, showing in vivo accumulation in pathologic tissues by recognizing disease-specific targets, could be useful for SPECT-diagnosis in nuclear medicine. Because of its low cost, widespread availability and ideal physical properties, Tc-99m is the isotope of choice for SPECT-imaging. Therefore, methods for high yield synthesis of conjugates between aptamers and Tc-99m binding cores and protocols for efficient Tc-99m-labelings of prepared conjugates have to be established. In the last years several conjugates between HYNIC-, MAG₃- and N₄-chelators with antisense-ON's or DNA's have been synthesized and labeled successfully with Tc-99m^{2,3}. For in vivo applications unmodified RNA and DNA molecules are too unstable against digestion by endo- and exonucleases. Partial replacement of 2'-H atoms in DNA's and of 2'-OH groups in RNA's by e.g. 2'-amino-, 2'-methoxy- or 2'-fluoro-substituents in combination with 3'-caps generates molecules showing high stabilities against nuclease degradation. For preparation of N₃S-conjugated aptamers during solid phase synthesis or for postsynthetic

couplings to amino modified ON's in solution or on solid support an NHS-ester of 'Bu-S-protected mercaptoacetyl-(Gly)₂-OH **1** was synthesized and coupled to e.g. a L-Selectin binding RNA 5'-{NH₂-(CH₂)₆-O-P}-GGAGUCUUAGGCAGCGGUUU-UCGAGCUACUCC-3'-3'-dT (**2**). The RNA **2** is stabilized against enzymatic degradation by introduction of 2'-F atoms in each C- and U-unit and by capping the 3'-end with a 3'-3'-linked dT. The resulting RNA 5'-{'BuS-S-CH₂-CO-(Gly)₂-NH-(CH₂)₆-O-P}-GGAGUCUUAGGCAGCGGUUUUCGAGCUACUCC-3'-3'-dT (**3**) bears the protected N₃S-chelator fixed by an alkylphosphato linker to the 5'-end. The S-protecting group was cleaved by treatment of **3** with an excess of DTT. As analyzed by HPLC (Fig. 1) and TLC (Fig. 2), the Tc-99m-labeling of purified N₃S-RNA 5'-{HS-CH₂-CO-(Gly)₂-NH-(CH₂)₆-O-P}-GGAGUCUUAGGCAGCGGUUUUCGAGCUAC-UCC-3'-3'-dT (**4**) was achieved with 95% radiochemical yield. PAGE-analysis (Fig. 3) of Tc-99m-labeled **4** showed one major band confirming the formation of the 1:1-Tc-99m complex **5**. Alternatively, the protected N₃S-RNA **3** was directly radiolabeled to the Tc-99m complex **5** (90% yield). In conclusion, S-protected MAG₂ building blocks were developed and coupled with good yields to amino-modified RNA's and DNA's in solution or on solid support. The prepared MAG₂-amide-oligonucleotides were Tc-99m-labeled with good yields and specific activities of 37MBq/nmol leading to 1:1-Tc-99m N₃S-aptamers.

REFERENCES

1. Gold, L.; Polisky, B.; Uhlenbeck, O.; Yarus, M. *Annual Rev. Biochem.*, **1995**, *64*, 763-797.
2. Winnard, P.; Chang, F.; Rusckowski, M.; Mardirossian, G.; Hnatowich, D.J. *Nucl. Med. & Biol.*, **1997**, *24*, 425-432.
3. Wagner, S.; Eisenhut, M.; Eritja, R.; Oberdorfer, F. *Nucleosides & Nucleotides*, **1997**, *16*, 1789-1792.